ArticleCancer medicine2022

Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).

Kazuyuki Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.